Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONQUER study of galcanezumab in treatment-resistant migraine
NL-OMON46150Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing Galcanezumab with Placebo (2 arms). Primary endpoint: Overall mean change from baseline in monthly migraine headache days. Started Dec 2018; status: active, not recruiting.
02
Drugs
galcanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NL-OMON46150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46150.